Literature DB >> 30361829

A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.

Tadashi Kumamoto1, Yuki Aoki2, Tomoko Sonoda2, Miho Yamanishi3, Ayumu Arakawa2, Masanaka Sugiyama2, Nami Shirakawa2, Sae Ishimaru2, Yoshimasa Saito4, Akiko Maeshima5, Miho Maeda3, Chitose Ogawa2.   

Abstract

Histiocytic sarcoma in advanced clinical stages is typically an aggressive neoplasm, with poor response to conventional chemotherapy. An 18-year-old male with refractory histiocytic sarcoma that had transformed from Rosai-Dorfman disease was admitted to our hospital. A pathogenic variant of MAP2K1 was detected by next-generation sequencing of tumor specimens. Affected regions showed excellent responses to the MEK inhibitor trametinib. It has been reported that RAS/MEK/ERK pathway is activated in many cases of histiocytic sarcoma. MEK inhibition may represent a useful treatment option in histiocytic sarcoma.

Entities:  

Keywords:  Histiocytic sarcoma; MAP2K1; MEK inhibitor; Rosai–Dorfman disease; Trametinib

Mesh：

Substances：

Year:  2018        PMID： 30361829     DOI： 10.1007/s12185-018-2553-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  13 in total

1.  Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.

Authors:  Sofia Garces; L Jeffrey Medeiros; Keyur P Patel; Shaoying Li; Sergio Pina-Oviedo; Jingyi Li; Juan C Garces; Joseph D Khoury; C Cameron Yin
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

2.  Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.

Authors:  Barbara C Worst; Cornelis M van Tilburg; Gnana Prakash Balasubramanian; Petra Fiesel; Ruth Witt; Angelika Freitag; Miream Boudalil; Christopher Previti; Stephan Wolf; Sabine Schmidt; Sasithorn Chotewutmontri; Melanie Bewerunge-Hudler; Matthias Schick; Matthias Schlesner; Barbara Hutter; Lenka Taylor; Tobias Borst; Christian Sutter; Claus R Bartram; Till Milde; Elke Pfaff; Andreas E Kulozik; Arend von Stackelberg; Roland Meisel; Arndt Borkhardt; Dirk Reinhardt; Jan-Henning Klusmann; Gudrun Fleischhack; Stephan Tippelt; Uta Dirksen; Heribert Jürgens; Christof M Kramm; Andre O von Bueren; Frank Westermann; Matthias Fischer; Birgit Burkhardt; Wilhelm Wößmann; Michaela Nathrath; Stefan S Bielack; Michael C Frühwald; Simone Fulda; Thomas Klingebiel; Ewa Koscielniak; Matthias Schwab; Roman Tremmel; Pablo Hernáiz Driever; Johannes H Schulte; Benedikt Brors; Andreas von Deimling; Peter Lichter; Angelika Eggert; David Capper; Stefan M Pfister; David T W Jones; Olaf Witt
Journal:  Eur J Cancer       Date:  2016-07-29       Impact factor: 9.162

3.  Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Authors:  Sophie Voruz; Anne Cairoli; Olaia Naveiras; Laurence de Leval; Edoardo Missiaglia; Krisztian Homicsko; Olivier Michielin; Sabine Blum
Journal:  Haematologica       Date:  2017-11-02       Impact factor: 9.941

4.  Histiocytic and dendritic cell neoplasms: what have we learnt by studying 67 cases.

Authors:  Fabio Facchetti; Stefano Aldo Pileri; Luisa Lorenzi; Valentina Tabanelli; Lisa Rimsza; Stefania Pittaluga; Stephan Dirnhofer; Christiane Copie-Bergman; Laurence de Leval; Andreas Rosenwald; Andrew Wotherspoon; Falko Fend
Journal:  Virchows Arch       Date:  2017-07-10       Impact factor: 4.064

5.  Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.

Authors:  Xuejun Tian; Jie Xu; Christopher Fletcher; Jason L Hornick; David M Dorfman
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

6.  MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.

Authors:  Maria E Arcila; Alexander Drilon; Brooke E Sylvester; Christine M Lovly; Laetitia Borsu; Boris Reva; Mark G Kris; David B Solit; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2014-10-28       Impact factor: 12.531

7.  Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms.

Authors:  Heounjeong Go; Yoon Kyung Jeon; Jooryung Huh; Suk Jin Choi; Yoo-Duk Choi; Hee Jeong Cha; Hyun-Jung Kim; Gyeongsin Park; Sookee Min; Ji Eun Kim
Journal:  Histopathology       Date:  2014-05-12       Impact factor: 5.087

8.  Somatic mutations in histiocytic sarcoma identified by next generation sequencing.

Authors:  Qingqing Liu; Keith Tomaszewicz; Lloyd Hutchinson; Jason L Hornick; Bruce Woda; Hongbo Yu
Journal:  Virchows Arch       Date:  2016-06-03       Impact factor: 4.064

9.  Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.

Authors:  Marian H Harris; Steven G DuBois; Julia L Glade Bender; AeRang Kim; Brian D Crompton; Erin Parker; Ian P Dumont; Andrew L Hong; Dongjing Guo; Alanna Church; Kimberly Stegmaier; Charles W M Roberts; Suzanne Shusterman; Wendy B London; Laura E MacConaill; Neal I Lindeman; Lisa Diller; Carlos Rodriguez-Galindo; Katherine A Janeway
Journal:  JAMA Oncol       Date:  2016-05-01       Impact factor: 31.777

10.  Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.

Authors:  Rajen J Mody; Yi-Mi Wu; Robert J Lonigro; Xuhong Cao; Sameek Roychowdhury; Pankaj Vats; Kevin M Frank; John R Prensner; Irfan Asangani; Nallasivam Palanisamy; Jonathan R Dillman; Raja M Rabah; Laxmi Priya Kunju; Jessica Everett; Victoria M Raymond; Yu Ning; Fengyun Su; Rui Wang; Elena M Stoffel; Jeffrey W Innis; J Scott Roberts; Patricia L Robertson; Gregory Yanik; Aghiad Chamdin; James A Connelly; Sung Choi; Andrew C Harris; Carrie Kitko; Rama Jasty Rao; John E Levine; Valerie P Castle; Raymond J Hutchinson; Moshe Talpaz; Dan R Robinson; Arul M Chinnaiyan
Journal:  JAMA       Date:  2015-09-01       Impact factor: 56.272
View more
  1 in total

Review 1.  Histiocytic and dendritic cell neoplasms of the mediastinum.

Authors:  Ezra Baraban; Kumarasen Cooper
Journal:  Mediastinum       Date:  2020-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.